Amorce Lima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amorce Lima has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Suzane Silbert
Esoteric Testing/R&D Laboratory, Tampa General Hospital, 1 Tampa General Circle, Tampa, FL 33606, USA
5 shared publicationsDominic Uy
Tampa General Hospital, Tampa, FL
3 shared publications- Suzane Silbert
Tampa General Hospital
3 shared publications Joshua Kostera
Abbott Laboratories, Des Plaines, IL
2 shared publicationsLaura Rowe
Esoteric Testing/R&D Laboratory, Tampa General Hospital, 1 Tampa General Circle, Tampa, FL 33606, USA
2 shared publicationsVicki Healer
Esoteric Testing Laboratory, Pathology Department, Tampa General Hospital, Tampa, FL, United States of America
2 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (10) , 723-731
Validation of a Semiquantitative Real-Time PCR Assay for Malaria Diagnosis and Treatment Monitoring
- 20 July 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (10) , 723-731
Open AccessValidation of a Semiquantitative Real-Time PCR Assay for Malaria Diagnosis and Treatment Monitoring
- 14 March 2024
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 109 (2) , 116265
Validation of a new extraction-free real-time PCR test to detect MPOX virus
- 14 March 2024
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 109 (2) , 116265
Validation of a new extraction-free real-time PCR test to detect MPOX virus
- Open Access
- 4 March 2024
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 51 (7) , 480-485
Clinical Evaluation of the Alinity m STI Multiplex PCR Assay
Background: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are routinely tested and reported; however, Trichomonas vaginalis (TV) is the most common sexually transmitted infection (STI) in the United States and the prevalence of Mycoplasma genitalium (MG) infections is likely higher than estimated. We examined the clinical performance of the Alinity m STI assay for detection and surveillance of CT/NG/TV/MG in urine specimens from patients at a large academic medical center. Methods: Urine specimen from 198 patients was tested in this evaluation. Alinity m STI and Aptima Combo 2 CT/NG and TV assay (Panther System) results were compared, with discrepant results run on the cobas 6800 CT/NG, TV/MG assays. Analyzer turnaround times, time from loading the specimen on the analyzer to results reporting, were determined for Alinity m and Panther systems. Results: Overall percent agreements of the Alinity m in comparison with the Aptima and cobas assays for CT, NG, TV, and MG were 99.5% (97.2%, 99.9%), 99.5% (97.2%, 99.9%), 98.4% (95.5%, 99.5%), and 86.4% (66.7%, 95.3), respectively. There were 5 discrepant samples (CT, 1; NG, 1; TV, 3) between the Alinity m and the Aptima assays, and 3 MG discrepant samples between the Alinity m STI and cobas 6800. Two of the 5 Aptima and Alinity m discrepant samples were resolved as they yielded similar results on both Alinity m and cobas 6800. TV and MG infections comprised 54% of the positive samples and were more often asymptomatic than CT and NG infections. Analyzer turnaround time was 3 hours 25 minutes for the Aptima CT/NG, 3 hours 25 minutes for Aptima TV, and 1 hour 55 minutes for Alinity m STI assay. Conclusions: The Alinity m STI assay allows for fast and simultaneous detection of the 4 major STI pathogens, which can facilitate surveillance and provide accurate results to help clinicians diagnose for initiation of appropriate treatment.
- 4 March 2024
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 51 (7) , 480-485
Open AccessClinical Evaluation of the Alinity m STI Multiplex PCR Assay
Background: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are routinely tested and reported; however, Trichomonas vaginalis (TV) is the most common sexually transmitted infection (STI) in the United States and the prevalence of Mycoplasma genitalium (MG) infections is likely higher than estimated. We examined the clinical performance of the Alinity m STI assay for detection and surveillance of CT/NG/TV/MG in urine specimens from patients at a large academic medical center. Methods: Urine specimen from 198 patients was tested in this evaluation. Alinity m STI and Aptima Combo 2 CT/NG and TV assay (Panther System) results were compared, with discrepant results run on the cobas 6800 CT/NG, TV/MG assays. Analyzer turnaround times, time from loading the specimen on the analyzer to results reporting, were determined for Alinity m and Panther systems. Results: Overall percent agreements of the Alinity m in comparison with the Aptima and cobas assays for CT, NG, TV, and MG were 99.5% (97.2%, 99.9%), 99.5% (97.2%, 99.9%), 98.4% (95.5%, 99.5%), and 86.4% (66.7%, 95.3), respectively. There were 5 discrepant samples (CT, 1; NG, 1; TV, 3) between the Alinity m and the Aptima assays, and 3 MG discrepant samples between the Alinity m STI and cobas 6800. Two of the 5 Aptima and Alinity m discrepant samples were resolved as they yielded similar results on both Alinity m and cobas 6800. TV and MG infections comprised 54% of the positive samples and were more often asymptomatic than CT and NG infections. Analyzer turnaround time was 3 hours 25 minutes for the Aptima CT/NG, 3 hours 25 minutes for Aptima TV, and 1 hour 55 minutes for Alinity m STI assay. Conclusions: The Alinity m STI assay allows for fast and simultaneous detection of the 4 major STI pathogens, which can facilitate surveillance and provide accurate results to help clinicians diagnose for initiation of appropriate treatment.
- Open Access
Comparative Clinical Evaluation of the Alinity m STI Multiplex PCR Assay for Diagnosis and Surveillance of Chlamydia trachomatis , Neisseria gonorrhea , Trichomonas vaginalis , and Mycoplasma genitalium
Background: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are routinely tested and reported; however, Trichomonas vaginalis (TV) is the most common STI in the US and the prevalence of Mycoplasma genitalium (MG) infections is likely higher than estimated. We examined the clinical performance of the Alinity m STI assay for detection and surveillance of CT/NG/TV/MG in urine specimens from patients at a large academic medical center. Methods: Prevalence of mono- and co-infections on Alinity m STI pathogens and predictors of a positive result were identified. Alinity m STI and Aptima Combo 2 CT/NG and TV assay (Panther System) results were compared, with discrepant results run on the cobas 6800 CT/NG, TV and MG assays. Analyzer turnaround times (TAT) were determined for Alinity m and Panther systems. Results: 199 urine specimens were included. Age ≥25 years, collection outside the emergency department (ED), and asymptomatic status were predictive of TV or MG infection; symptomatic status was the only predictor of CT or NG infection. Overall agreement rates for the Alinity m, Aptima, and cobas assays ranged from 86.4% to 99.5% for the four pathogens. TV and MG infections comprised 54% of the positive samples and were more often asymptomatic than CT and NG infections. Analyzer TAT (onboard to result reporting) was 4 hours 45 minutes for the Aptima CT/NG, 3 hours 25 minutes for Aptima TV, and 1 hour 55 minutes for Alinity m STI assay. Conclusions: The Alinity m STI assay allows for fast and simultaneous detection of the four major STI pathogens, which can facilitate surveillance and provide accurate results to help clinicians diagnose for initiation of appropriate treatment.
Open AccessComparative Clinical Evaluation of the Alinity m STI Multiplex PCR Assay for Diagnosis and Surveillance of Chlamydia trachomatis , Neisseria gonorrhea , Trichomonas vaginalis , and Mycoplasma genitalium
Background: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are routinely tested and reported; however, Trichomonas vaginalis (TV) is the most common STI in the US and the prevalence of Mycoplasma genitalium (MG) infections is likely higher than estimated. We examined the clinical performance of the Alinity m STI assay for detection and surveillance of CT/NG/TV/MG in urine specimens from patients at a large academic medical center. Methods: Prevalence of mono- and co-infections on Alinity m STI pathogens and predictors of a positive result were identified. Alinity m STI and Aptima Combo 2 CT/NG and TV assay (Panther System) results were compared, with discrepant results run on the cobas 6800 CT/NG, TV and MG assays. Analyzer turnaround times (TAT) were determined for Alinity m and Panther systems. Results: 199 urine specimens were included. Age ≥25 years, collection outside the emergency department (ED), and asymptomatic status were predictive of TV or MG infection; symptomatic status was the only predictor of CT or NG infection. Overall agreement rates for the Alinity m, Aptima, and cobas assays ranged from 86.4% to 99.5% for the four pathogens. TV and MG infections comprised 54% of the positive samples and were more often asymptomatic than CT and NG infections. Analyzer TAT (onboard to result reporting) was 4 hours 45 minutes for the Aptima CT/NG, 3 hours 25 minutes for Aptima TV, and 1 hour 55 minutes for Alinity m STI assay. Conclusions: The Alinity m STI assay allows for fast and simultaneous detection of the four major STI pathogens, which can facilitate surveillance and provide accurate results to help clinicians diagnose for initiation of appropriate treatment.
- Open Access
- 22 April 2023
- Published by Elsevier in Journal of Clinical Virology
- Vol. 164, 105467
Performance evaluation of the Aptima CMV quant assay using plasma and non-plasma samples
- 22 April 2023
- Published by Elsevier in Journal of Clinical Virology
- Vol. 164, 105467
Open AccessPerformance evaluation of the Aptima CMV quant assay using plasma and non-plasma samples
- Open Access
- 1 August 2020
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 97 (4) , 115055
Evaluation of Copan FecalSwab™ preserved stool specimens with the BD MAX™ Enteric Bacterial Panel and the BD MAX™ Extended Enteric Bacterial Panel
- 1 August 2020
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 97 (4) , 115055
Open AccessEvaluation of Copan FecalSwab™ preserved stool specimens with the BD MAX™ Enteric Bacterial Panel and the BD MAX™ Extended Enteric Bacterial Panel
- Open Access
Validation and Comparison of a Modified CDC Assay with two Commercially Available Assays for the Detection of SARS-CoV-2 in Respiratory Specimen
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has spread rapidly around the globe since it was first identified in December of 2019 in Wuhan, China. In a race to contain the infection, researchers and healthcare officials have developed several assays to help diagnose individuals with COVID-19. To help laboratories in deciding what assay to bring into testing lines, factors such as assay availability, cost, throughput, and TAT should be considered. Here we validated a modified version of the CDC assay and used it as a reference to evaluate the performance of the NeuMoDx™ SARS-CoV-2 and DiaSorin Simplexa™ Covid-19 Direct assays. In silico analysis and clinical sample testing showed that the primesr/probes designed by the CDC were specific to the SARS-CoV-2 as they accurately detected all reactive samples with an assay LoD of 200 copies/ml. The performance of the three assays were analyzed using 161 nasopharyngeal swabs specimen tested within 24 hours or 5 days from routine testing. A 100% agreement was observed between the commercial assays and the modified CDC SARS-CoV-2 assay. A deeper look at the Ct values showed no significant difference between NeuMoDx and the modified CDC SARS-CoV-2 assay, whereas DiaSorin had lower overall Ct values than the modified CDC SARS-CoV-2 assay. NeuMoDx and DiaSorin workflows were much easier to perform. NeuMoDx has the highest throughput and shortest TAT, whereas although the modified CDC SARS-CoV-2 assay has comparable throughput to DiaSorin, it has the longest hands-on time, and highest TAT.
Open AccessValidation and Comparison of a Modified CDC Assay with two Commercially Available Assays for the Detection of SARS-CoV-2 in Respiratory Specimen
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has spread rapidly around the globe since it was first identified in December of 2019 in Wuhan, China. In a race to contain the infection, researchers and healthcare officials have developed several assays to help diagnose individuals with COVID-19. To help laboratories in deciding what assay to bring into testing lines, factors such as assay availability, cost, throughput, and TAT should be considered. Here we validated a modified version of the CDC assay and used it as a reference to evaluate the performance of the NeuMoDx™ SARS-CoV-2 and DiaSorin Simplexa™ Covid-19 Direct assays. In silico analysis and clinical sample testing showed that the primesr/probes designed by the CDC were specific to the SARS-CoV-2 as they accurately detected all reactive samples with an assay LoD of 200 copies/ml. The performance of the three assays were analyzed using 161 nasopharyngeal swabs specimen tested within 24 hours or 5 days from routine testing. A 100% agreement was observed between the commercial assays and the modified CDC SARS-CoV-2 assay. A deeper look at the Ct values showed no significant difference between NeuMoDx and the modified CDC SARS-CoV-2 assay, whereas DiaSorin had lower overall Ct values than the modified CDC SARS-CoV-2 assay. NeuMoDx and DiaSorin workflows were much easier to perform. NeuMoDx has the highest throughput and shortest TAT, whereas although the modified CDC SARS-CoV-2 assay has comparable throughput to DiaSorin, it has the longest hands-on time, and highest TAT.
- Open Access
- 1 July 2019
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 57 (7)
A TaqMan Probe-Based Real-Time PCR Assay for the Rapid Identification of the Emerging Multidrug-Resistant Pathogen Candida auris on the BD Max System
Candida auris is an emerging multidrug-resistant fungal pathogen that has been associated with nosocomial bloodstream and deep wound infections causing a high mortality rate mainly in intensive care unit (ICU) patients. Laboratories currently rely on phenotypic testing using commercial automated systems for identification of yeasts; however, this technique has often led to misidentification of C. auris to other closely related species.
- 1 July 2019
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 57 (7)
Open AccessA TaqMan Probe-Based Real-Time PCR Assay for the Rapid Identification of the Emerging Multidrug-Resistant Pathogen Candida auris on the BD Max System
Candida auris is an emerging multidrug-resistant fungal pathogen that has been associated with nosocomial bloodstream and deep wound infections causing a high mortality rate mainly in intensive care unit (ICU) patients. Laboratories currently rely on phenotypic testing using commercial automated systems for identification of yeasts; however, this technique has often led to misidentification of C. auris to other closely related species.